Efficacy of Trikafta (ELX/TEZ/IVA) & Symdeko (TEZ/IVA) in Treating Cystic Fibrosis with F508del Allele: A Systematic Review and Meta-analysis
The objective of the study was to assess and compare the efficacy of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) treatment with TEZ/IVA treatment in individuals diagnosed with cystic fibrosis (CF) and carrying the F508del allele. An extensive search of relevant literature was conducted using onli...
Saved in:
| Main Authors: | Kainat Hussain, Sonali Karhana, Aakriti Garg, Mohd Ashif Khan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos
2025-09-01
|
| Series: | Thoracic Research and Practice |
| Subjects: | |
| Online Access: | https://thoracrespract.org/articles/efficacy-of-trikafta-elxteziva-andamp-symdeko-teziva-in-treating-cystic-fibrosis-with-f508del-allele-a-systematic-review-and-meta-analysis/doi/ThoracResPract.2025.2025-1-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI)
by: Tomke Sütering, et al.
Published: (2024-12-01) -
Blood platelet reduction after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction
by: Alice Castaldo, et al.
Published: (2025-07-01) -
Advances in the treatment of cystic fibrosis: CFTR modulators
by: Maria Dolores Pastor-Vivero, et al.
Published: (2025-05-01) -
Avances en el tratamiento de la fibrosis quística: los moduladores de la CFTR
by: Maria Dolores Pastor-Vivero, et al.
Published: (2025-05-01) -
Improved Clinical Outcomes With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease: Real‐World Evidence From an Italian Single‐Center Study
by: Nicola Perrotta, et al.
Published: (2025-04-01)